BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) CEO Jean Jacques Bienaime sold 10,000 shares of the company’s stock in a transaction that occurred on Friday, January 5th. The stock was sold at an average price of $90.32, for a total transaction of $903,200.00. Following the completion of the transaction, the chief executive officer now owns 235,894 shares in the company, valued at approximately $21,305,946.08. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.
Jean Jacques Bienaime also recently made the following trade(s):
- On Saturday, December 29th, Jean Jacques Bienaime sold 10,000 shares of BioMarin Pharmaceutical stock. The shares were sold at an average price of $89.61, for a total transaction of $896,100.00.
- On Friday, December 29th, Jean Jacques Bienaime sold 20,000 shares of BioMarin Pharmaceutical stock. The shares were sold at an average price of $89.75, for a total transaction of $1,795,000.00.
BioMarin Pharmaceutical Inc. (NASDAQ BMRN) traded up $0.02 during mid-day trading on Tuesday, reaching $90.24. 1,423,500 shares of the company’s stock traded hands, compared to its average volume of 1,280,000. The company has a market capitalization of $15,850.00, a price-to-earnings ratio of -108.72 and a beta of 1.81. The company has a quick ratio of 3.81, a current ratio of 4.91 and a debt-to-equity ratio of 0.41. BioMarin Pharmaceutical Inc. has a fifty-two week low of $80.10 and a fifty-two week high of $100.51.
BioMarin Pharmaceutical (NASDAQ:BMRN) last released its earnings results on Thursday, October 26th. The biotechnology company reported ($0.07) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.13) by $0.06. The firm had revenue of $334.18 million during the quarter, compared to analyst estimates of $347.38 million. BioMarin Pharmaceutical had a negative net margin of 12.45% and a negative return on equity of 4.60%. The business’s revenue was up 19.4% on a year-over-year basis. During the same quarter last year, the business earned $0.02 EPS. research analysts anticipate that BioMarin Pharmaceutical Inc. will post -0.64 EPS for the current fiscal year.
A number of research analysts recently weighed in on BMRN shares. Piper Jaffray Companies reiterated a “buy” rating and issued a $113.00 price target on shares of BioMarin Pharmaceutical in a research report on Thursday, September 21st. Jefferies Group reiterated a “buy” rating and issued a $116.00 price target on shares of BioMarin Pharmaceutical in a research report on Tuesday, September 26th. Morgan Stanley reiterated an “overweight” rating and issued a $117.00 price target (up from $115.00) on shares of BioMarin Pharmaceutical in a research report on Friday, October 6th. Goldman Sachs Group reiterated a “buy” rating and issued a $129.00 price target on shares of BioMarin Pharmaceutical in a research report on Friday, October 6th. Finally, Zacks Investment Research cut shares of BioMarin Pharmaceutical from a “hold” rating to a “sell” rating in a research note on Monday, October 16th. Two investment analysts have rated the stock with a sell rating, seven have issued a hold rating, sixteen have assigned a buy rating and one has assigned a strong buy rating to the stock. BioMarin Pharmaceutical presently has an average rating of “Buy” and an average price target of $112.14.
A number of institutional investors and hedge funds have recently made changes to their positions in BMRN. Schwab Charles Investment Management Inc. increased its position in BioMarin Pharmaceutical by 8.1% during the 2nd quarter. Schwab Charles Investment Management Inc. now owns 298,243 shares of the biotechnology company’s stock valued at $27,087,000 after purchasing an additional 22,433 shares during the period. Comerica Bank increased its position in BioMarin Pharmaceutical by 1.0% during the 2nd quarter. Comerica Bank now owns 7,358 shares of the biotechnology company’s stock valued at $662,000 after purchasing an additional 76 shares during the period. Prudential Financial Inc. increased its position in BioMarin Pharmaceutical by 2.9% during the 2nd quarter. Prudential Financial Inc. now owns 145,170 shares of the biotechnology company’s stock valued at $13,185,000 after purchasing an additional 4,026 shares during the period. Cambridge Investment Research Advisors Inc. purchased a new position in BioMarin Pharmaceutical during the 2nd quarter valued at about $213,000. Finally, Los Angeles Capital Management & Equity Research Inc. purchased a new position in BioMarin Pharmaceutical during the 2nd quarter valued at about $3,015,000. Institutional investors own 99.15% of the company’s stock.
WARNING: “BioMarin Pharmaceutical Inc. (BMRN) CEO Sells $903,200.00 in Stock” was reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this news story on another publication, it was stolen and republished in violation of United States and international trademark and copyright legislation. The correct version of this news story can be viewed at https://www.dispatchtribunal.com/2018/01/16/insider-selling-biomarin-pharmaceutical-inc-bmrn-ceo-sells-10000-shares-of-stock.html.
About BioMarin Pharmaceutical
BioMarin Pharmaceutical Inc is a biotechnology company. The Company develops and commercializes pharmaceuticals for various diseases and medical conditions. As of December 31, 2016, the Company’s therapy portfolio consisted of five products, and multiple clinical and pre-clinical product candidates. Its commercial products include Aldurazyme (laronidase) for Mucopolysaccharidosis I (MPS I), Firdapse (amifampridine phosphate) for Lambert Eaton Myasthenic Syndrome (LEMS), Kuvan (sapropterin dihydrochloride) for phenylketonuria (PKU), Naglazyme (galsulfase) for Mucopolysaccharidosis VI (MPS VI) and Vimizim (elosulfase alpha) for Mucopolysaccharidosis IV Type A (MPS IV A).
Receive News & Ratings for BioMarin Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioMarin Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.